Dual targeting of epigenetic therapy in cancer

Aberrant epigenetic silencing of tumor suppressor genes by promoter DNA hypermethylation and histone deacetylation plays an important role in the pathogenesis of cancer. The potential reversibility of epigenetic abnormalities encouraged the development of pharmacologic inhibitors of DNA methylation and histone deacetylation as anti-cancer therapeutics. (Pre)clinical studies of DNA methyltransferase (DNMT) and histone deacetylase (HDAC) inhibitors have yielded encouraging results, especially against hematologic malignancies. Recently, several studies demonstrated that DNMT and HDAC inhibitors are also potent angiostatic agents, inhibiting (tumor) endothelial cells and angiogenesis in vitro and in vivo. By reactivation of epigenetically silenced tumor suppressor genes with angiogenesis inhibiting properties, DNMT and HDAC inhibitors might indirectly - via their effects on tumor cells - decrease tumor angiogenesis in vivo. However, this does not explain the direct angiostatic effects of these agents, which can be unraveled by gene expression studies and examination of epigenetic promoter modifications in endothelial cells treated with DNMT and HDAC inhibitors. Clearly, the dual targeting of epigenetic therapy on both tumor cells and tumor vasculature makes them attractive combinatorial anti-tumor therapeutics. Here we review the therapeutic potential of DNMT and HDAC inhibitors as anti-cancer drugs, as evaluated in clinical trials, and their angiostatic activities, apart from their inhibitory effects on tumor cells.     

Unraveling the epigenetic code of cancer for therapy

Alterations in the genome and the epigenome are common in most cancers. Changes in epigenetic signatures, including aberrant DNA methylation and histone deacetylation, are among the most prevalent modifications in cancer and lead to dramatic changes in gene expression patterns. Because DNA methylation and histone deacetylation are reversible processes, they have become attractive as targets for cancer epigenetic therapy, both as single agents and as 'enhancing' agents for other treatment strategies. In this review we discuss our current view of the mammalian epigenome, this view has changed over the years because of the availability of novel technologies. We further demonstrate how the profound understanding of epigenetic alterations in cancer will help develop novel strategies for epigenetic therapies.     

Epigenomics and chromatin dynamics

A report of the 'Joint Keystone Symposium on Epigenomics and Chromatin Dynamics', Keystone, Colorado, 17-22 January 2012.     

Towards a more precise therapy in cancer: Exploring epigenetic complexity

A plethora of preclinical evidences suggests that pharmacological targeting of epigenetic dysregulation is a potent strategy to combat human diseases. Nevertheless, the implementation of epidrugs in clinical practice is very scarce and mainly limited to haematological malignancies. In this review, we discuss cutting-edge strategies to foster the chemical design, the biological rationale and the clinical trial development of epidrugs. Specifically, we focus on the development of dual hybrids to exploit multitargeting of key epigenetic molecules deregulated in cancer; the study of epigenetic-synthetic lethality interactions as a mechanism to address loss-of-function mutations, and the combination of epidrugs with other therapies such as immunotherapy to avoid acquired chemoresistance and increase therapy sensitivity. By exploring these challenges, among others, the field of epigenetic chemical biology will increase its potential for clinical benefit, and more effective strategies targeting the aberrant epigenome in cancer are likely to be developed both in haematological and solid tumours.     

表观遗传学与人类表观基因组计划

表观遗传学已被用来描述许多生物学过程,成为生物学与医学领域中热点的学科之一.本文简要介绍表观遗传学与表观遗传基因组学的概念、人类表观基因组计划研究的目标与意义,并阐述DNA甲基化、组蛋白修饰、染色质重塑和非编码微小RNA等表观遗传学调控基因表达的机制.我们已经认识到人类疾病基因缺损可能部分或完全与表观遗传有关.所以,研究疾病状态下非突变的、可逆的表观遗传调节,以及治疗的可能性具有重要实际意义.     

肿瘤表观基因组学研究进展

多年来遗传学改变一直是肿瘤研究的焦点,近来人们越来越认识到异常表观遗传修饰在肿瘤形成中所起的重要作用。表观遗传修饰包括DNA甲基化、组蛋白修饰等,其变异会导致基因转录异常。表观基因组学是在基因组水平上对表观遗传学改变的研究。文章主要介绍目前已知的肿瘤表观基因组学相关内容,阐述表观遗传修饰与肿瘤的紧密关系及异常表观遗传修饰作为生物标记在肿瘤诊断、预后及治疗方面的最新研究进展。     

Senescence and epigenetic dysregulation in cancer

Mammalian cells have a finite proliferative lifespan, at the end of which they are unable to enter S phase in response to mitogenic stimuli. They undergo morphological changes and synthesize an altered repertoire of cell type-specific proteins. This non-proliferative state is termed replicative senescence and is regarded as a major tumor suppressor mechanism. The ability to overcome senescence and obtain a limitless replicative potential is called immortalization, and considered to be one of the prerequisites of cancer formation. While senescence mainly represents a genetically governed process, epigenetic changes in cancer have received increasing attention as an alternative mechanism for mediating gene expression changes in transformed cells. DNA methylation of promoter-containing CpG islands has emerged as an epigenetic mechanism of silencing tumor suppressor genes. New insights are being gained into the mechanisms causing aberrant methylation in cancer and evidence suggests that aging is accompanied by accumulation of cells with aberrant CpG island methylation. Aberrant methylation may contribute to many of the physiological and pathological changes associated with aging including tumor development. Finally, we describe how genes involved in promoting longevity might inhibit pathways promoting tumorigenesis.     

Genetic and epigenetic heterogeneity of epithelial ovarian cancer and the clinical implications for molecular targeted therapy

Epithelial ovarian cancer (EOC) is the most lethal gynaecological malignancy, and tumoural heterogeneity (TH) has been blamed for treatment failure. The genomic and epigenomic atlas of EOC varies significantly with tumour histotype, grade, stage, sensitivity to chemotherapy and prognosis. Rapidly accumulating knowledge about the genetic and epigenetic events that control TH in EOC has facilitated the development of molecular‐targeted therapy. Poly (ADP‐ribose) polymerase (PARP) inhibitors, designed to target homologous recombination, are poised to change how breast cancer susceptibility gene (BRCA)‐related ovarian cancer is treated. Epigenetic treatment regimens being tested in clinical or preclinical studies could provide promising novel treatment approaches and hope for improving patient survival.     

Genetic and epigenetic aspects of bladder cancer

Transitional cell carcinoma of the urinary bladder has a diverse collection of biologic and functional characteristics. This is reflected in differing clinical courses. The diagnosis of bladder cancer is based on the information provided by cystoscopy, the gold standard in combination with urinary cytology findings. Many tumor markers have been evaluated for detecting and monitoring the disease in serum, bladder washes, and urinary specimens. However, none of these biomarkers reported to date has shown sufficient sensitivity and specificity for the detection of the whole spectrum of bladder cancer diseases in routine clinical practice. The limited value of established prognostic markers requires the analysis of new molecular parameters of interest in predicting the prognosis of bladder cancer patients; in particular, the high-risk patient groups at risk of progression and recurrence. Over the past decade, there has been major progress elucidating of the molecular genetic and epigenetic changes leading to the development of transitional cell carcinoma. This review focuses on the recent advances of genetic and epigenetic aspects in bladder cancer, and emphasizes how molecular biology would be likely to affect the future therapies.     

Environmental Epigenomics,Imprinting and Disease Susceptibility

On Tuesday, November 2, 2005 over 450 scientists representing 14 nations converged on the Washington Duke Inn, Durham, NC, USA to discuss, learn and exchange information on how environmental influences can exert impacts on health not only on the individual that has been exposed but also for up to four subsequent generations in some human and animal models tested. The meeting entitled “Environmental Epigenomics, Imprinting and Disease Susceptibility” was sponsored by the National Institute of Environmental Health Sciences (NIEHS) and the Duke Comprehensive Cancer Center. The meeting featured presentations from many of the leading authorities/experts in epigenomics in the world and approximately 70 poster presentations, of which twelve were selected for oral presentation. The meeting was organized into nine scientific sessions spread over two and a half days that addressed the fetal basis of disease, epigenetics and gene regulation, epigenetics and cancer, therapeutic and reproductive cloning, stem cell differentiation, epigenetics and chronic diseases and epigenetics and neurodevelopment. The opening session introduced the meeting co-organizers, Randy Jirtle of Duke University Medical Center and Frederick Tyson of NIEHS, to conference participants and included greetings from. Christopher Willett, Chair of Duke Radiation Oncology Department, and William Schlessinger, Dean of the Nicolas School of the Environment and Earth Sciences. David Schwartz, Director of the NIEHS, set the tone for the conference with an overview lecture that identified research priorities of the NIEHS and pointed out the intersections between the environmental genomics component of NIEHS priorities and the environmental epigenomics. He noted that NIEHS research priorities will emphasize and coordinate efforts aimed at the study of complex human diseases. The environmental genomics infrastructural resources developed by NIEHS including over 500 re-sequenced environmentally responsive genes, over 50 humanized mouse strains, and progress towards establishing gene expression standards are available for utilization in the integration of epigenomic studies and the analysis of complex human diseases. Just as epigenomics is becoming increasingly more important in Schwartz’s own asthma research, this conference identified additional opportunities for the integration of environmental epigenomics and complex human disease.